Integrase-Defective Lentiviral Vector Is an Efficient Vaccine Platform for Cancer Immunotherapy
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Integrase-Defective Lentiviral Vector Is an Efficient Vaccine Platform for Cancer Immunotherapy
Authors
Keywords
-
Journal
Viruses-Basel
Volume 13, Issue 2, Pages 355
Publisher
MDPI AG
Online
2021-02-24
DOI
10.3390/v13020355
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Skeletal Muscle Is an Antigen Reservoir in Integrase-Defective Lentiviral Vector-Induced Long-Term Immunity
- (2020) Yi-Yu Lin et al. Molecular Therapy-Methods & Clinical Development
- CAR T Cell Therapy for Solid Tumors: Bright Future or Dark Reality?
- (2020) Jessica Wagner et al. MOLECULAR THERAPY
- The Old and the New: Prospects for Non-Integrating Lentiviral Vector Technology
- (2020) Luis Apolonia Viruses-Basel
- Turning the corner on therapeutic cancer vaccines
- (2019) Robert E. Hollingsworth et al. npj Vaccines
- Persistence of Integrase-Deficient Lentiviral Vectors Correlates with the Induction of STING-Independent CD8+ T Cell Responses
- (2019) Céline Cousin et al. Cell Reports
- Cancer immunotherapy using checkpoint blockade
- (2018) Antoni Ribas et al. SCIENCE
- Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy
- (2018) Aurélie Durgeau et al. Frontiers in Immunology
- Integrase Defective Lentiviral Vector as a Vaccine Platform for Delivering Influenza Antigens
- (2018) Alessandra Gallinaro et al. Frontiers in Immunology
- Designing consensus immunogens to break tolerance to self-antigens for cancer therapy
- (2018) Elizabeth K. Duperret et al. Oncotarget
- First-in-Human Treatment With a Dendritic Cell-targeting Lentiviral Vector-expressing NY-ESO-1, LV305, Induces Deep, Durable Response in Refractory Metastatic Synovial Sarcoma Patient
- (2017) Seth M. Pollack et al. JOURNAL OF IMMUNOTHERAPY
- Immunization with an SIV-based IDLV Expressing HIV-1 Env 1086 Clade C Elicits Durable Humoral and Cellular Responses in Rhesus Macaques
- (2016) Donatella Negri et al. MOLECULAR THERAPY
- LV305, a dendritic cell-targeting integration-deficient ZVex TM -based lentiviral vector encoding NY-ESO-1, induces potent anti-tumor immune response
- (2016) Tina Chang Albershardt et al. Molecular Therapy-Oncolytics
- Dissecting the Mechanism of Histone Deacetylase Inhibitors to Enhance the Activity of Zinc Finger Nucleases Delivered by Integrase-Defective Lentiviral Vectors
- (2014) Alok V. Joglekar et al. HUMAN GENE THERAPY
- Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
- (2014) Suzanne L. Topalian et al. JOURNAL OF CLINICAL ONCOLOGY
- Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
- (2014) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mucosal Immunization with Integrase-Defective Lentiviral Vectors Protects against Influenza Virus Challenge in Mice
- (2014) Judith M. Fontana et al. PLoS One
- Enhanced Vaccine-Induced CD8+ T Cell Responses to Malaria Antigen ME-TRAP by Fusion to MHC Class II Invariant Chain
- (2014) Alexandra J. Spencer et al. PLoS One
- Cytomegalovirus-based cancer vaccines expressing TRP2 induce rejection of melanoma in mice
- (2013) Guangwu Xu et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer
- (2013) L Bracci et al. CELL DEATH AND DIFFERENTIATION
- Lentiviral Hematopoietic Stem Cell Gene Therapy in Patients with Wiskott-Aldrich Syndrome
- (2013) A. Aiuti et al. SCIENCE
- Lentiviral Hematopoietic Stem Cell Gene Therapy Benefits Metachromatic Leukodystrophy
- (2013) A. Biffi et al. SCIENCE
- Vaccine Design for CD8 T Lymphocyte Responses
- (2013) R. A. Koup et al. Cold Spring Harbor Perspectives in Medicine
- Histone Deacetylase Inhibition Activates Transgene Expression from Integration-Defective Lentiviral Vectors in Dividing and Non-Dividing Cells
- (2012) Laetitia P.L. Pelascini et al. HUMAN GENE THERAPY
- Successful therapeutic vaccination with integrase defective lentiviral vector expressing nononcogenic human papillomavirus E7 protein
- (2012) Felicia Grasso et al. INTERNATIONAL JOURNAL OF CANCER
- Integrase-defective lentiviral-vector-based vaccine: a new vector for induction of T cell immunity
- (2011) Donatella RM Negri et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Alphavirus Replicon Particles Expressing TRP-2 Provide Potent Therapeutic Effect on Melanoma through Activation of Humoral and Cellular Immunity
- (2010) Francesca Avogadri et al. PLoS One
- Cellular mechanisms regulating human melanogenesis
- (2009) H. Y. Park et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- In vivo depletion of DC impairs the anti-tumor effect of agonistic anti-CD137 mAb
- (2009) Oihana Murillo et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Development and use of SIV-based Integrase defective lentiviral vector for immunization
- (2009) Zuleika Michelini et al. VACCINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now